Exact Mass: 591.1548

Exact Mass Matches: 591.1548

Found 37 metabolites which its exact mass value is equals to given mass value 591.1548, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Zafirlukast metabolite M5

cyclopentyl N-[1-(hydroxymethyl)-3-({2-methoxy-4-[(2-methylbenzenesulfonyl)carbamoyl]phenyl}methyl)-1H-indol-5-yl]carbamate

C31H33N3O7S (591.2039)


Zafirlukast metabolite M5 is a metabolite of zafirlukast. Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), taken once daily. Zileuton (Zyflo), also used in the treatment of asthma via its inhibition of 5-lipoxygenase, is taken four times per day. (Wikipedia)

   

(E)-3-(6-Acetamidopyridin-3-yl)-N-[2-[2,4-dichloro-N-methyl-3-[(2-methylquinolin-8-yl)oxymethyl]anilino]-2-oxoethyl]prop-2-enamide

(E)-3-(6-Acetamidopyridin-3-yl)-N-[2-[2,4-dichloro-N-methyl-3-[(2-methylquinolin-8-yl)oxymethyl]anilino]-2-oxoethyl]prop-2-enamide

C30H27Cl2N5O4 (591.144)


   
   

Tetra-Ac-2-Phenylethyl glucosinolate

Tetra-Ac-2-Phenylethyl glucosinolate

C23H29NO13S2 (591.108)


   

2-Hydroxyzafirlukast

2-Hydroxyzafirlukast

C31H33N3O7S (591.2039)


   

3-Hydroxyzafirlukast

3-Hydroxyzafirlukast

C31H33N3O7S (591.2039)


   

1-Hydroxyzafirlukast

1-Hydroxyzafirlukast

C31H33N3O7S (591.2039)


   

4-Hydroxyzafirlukast

4-Hydroxyzafirlukast

C31H33N3O7S (591.2039)


   

Fmoc-Glu(OtBu)-OPfp

Fmoc-Glu(OtBu)-OPfp

C30H26F5NO6 (591.168)


   

1,2,2,3,4,4-hexaphenyl-1,3,5,2,4,6-triazatrisilinane

1,2,2,3,4,4-hexaphenyl-1,3,5,2,4,6-triazatrisilinane

C36H33N3Si3 (591.1982)


   

N-Desmethyl Prochlorperazine Dimaleate

N-Desmethyl Prochlorperazine Dimaleate

C27H30ClN3O8S (591.1442)


   

Fiduxosin hydrochloride

Fiduxosin hydrochloride

C30H30ClN5O4S (591.1707)


C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist

   

(E)-3-(6-Acetamidopyridin-3-yl)-N-[2-[2,4-dichloro-N-methyl-3-[(2-methylquinolin-8-yl)oxymethyl]anilino]-2-oxoethyl]prop-2-enamide

(E)-3-(6-Acetamidopyridin-3-yl)-N-[2-[2,4-dichloro-N-methyl-3-[(2-methylquinolin-8-yl)oxymethyl]anilino]-2-oxoethyl]prop-2-enamide

C30H27Cl2N5O4 (591.144)


D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D065168 - Bradykinin Receptor Antagonists D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents

   

1-[2-[3-Carboxy-5-[[3-carboxy-3-(2-carboxy-2-hydroxy-5-oxopyrrolidin-1-yl)propyl]amino]-3-hydroxy-5-oxopentanoyl]oxyethyl]-2-hydroxy-5-oxopyrrolidine-2-carboxylic acid

1-[2-[3-Carboxy-5-[[3-carboxy-3-(2-carboxy-2-hydroxy-5-oxopyrrolidin-1-yl)propyl]amino]-3-hydroxy-5-oxopentanoyl]oxyethyl]-2-hydroxy-5-oxopyrrolidine-2-carboxylic acid

C22H29N3O16 (591.1548)


   

7-O-methylvitexin 2-O-beta-L-rhamnoside(1-)

7-O-methylvitexin 2-O-beta-L-rhamnoside(1-)

C28H31O14- (591.1714)


A flavonoid oxoanion obtained by deprotonation of the 5-hydroxy group of 7-O-methylvitexin 2-O-beta-L-rhamnoside. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).

   

2-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-6-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide

2-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-6-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide

C29H26F5N3O5 (591.1793)


   

2-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-6-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide

2-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-6-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide

C29H26F5N3O5 (591.1793)


   

2-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-6-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide

2-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-6-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide

C29H26F5N3O5 (591.1793)


   

2-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-6-[[4-(trifluoromethyl)phenyl]carbamoylamino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide

2-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-6-[[4-(trifluoromethyl)phenyl]carbamoylamino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide

C29H26F5N3O5 (591.1793)


   

2-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-6-[[4-(trifluoromethyl)phenyl]carbamoylamino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide

2-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-6-[[4-(trifluoromethyl)phenyl]carbamoylamino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide

C29H26F5N3O5 (591.1793)


   

2-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-6-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide

2-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-6-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide

C29H26F5N3O5 (591.1793)


   

2-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-6-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide

2-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-6-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide

C29H26F5N3O5 (591.1793)


   

2-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-6-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide

2-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-6-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide

C29H26F5N3O5 (591.1793)


   

Achromobactin free acid

Achromobactin free acid

C22H29N3O16 (591.1548)


   

7-O-methylvitexin 2-O-alpha-L-rhamnoside(1-)

7-O-methylvitexin 2-O-alpha-L-rhamnoside(1-)

C28H31O14- (591.1714)


   

alpha-2,6-Sialyllactose

alpha-2,6-Sialyllactose

C21H37NO18 (591.2011)


   

Neu(b2-3)Gal(b1-4)b-Glc

Neu(b2-3)Gal(b1-4)b-Glc

C21H37NO18 (591.2011)


   

Neu(a2-3)Gal(b1-4)b-Glc

Neu(a2-3)Gal(b1-4)b-Glc

C21H37NO18 (591.2011)


   

[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl [(1S,2R,3S,4S,5R,6S)-2,4-bis(diaminomethylideneamino)-3,5,6-trihydroxycyclohexyl] hydrogen phosphate

[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl [(1S,2R,3S,4S,5R,6S)-2,4-bis(diaminomethylideneamino)-3,5,6-trihydroxycyclohexyl] hydrogen phosphate

C18H30N11O10P (591.1915)


   

(2S)-6-(2,4-dinitroanilino)-2-[6-(2,4-dinitroanilino)hexanoylamino]hexanoic acid

(2S)-6-(2,4-dinitroanilino)-2-[6-(2,4-dinitroanilino)hexanoylamino]hexanoic acid

C24H29N7O11 (591.1925)


   

Zafirlukast metabolite M5

Zafirlukast metabolite M5

C31H33N3O7S (591.2039)


   

GSK2033

GSK2033

C29H28F3NO5S2 (591.1361)


GSK2033 is a LXR antagonist with pIC50s of 7 and 7.4 for LXRα or LXRβ, respectively.

   

24-ethyl-3,10,28-trihydroxy-14-methoxy-25-methyl-5,26-dioxo-12,18,20-trioxa-25-azaheptacyclo[15.11.1.0²,¹⁵.0⁴,¹³.0⁶,¹¹.0²¹,²⁹.0²²,²⁷]nonacosa-1(29),2(15),3,6(11),13,21,23,27-octaen-7-yl acetate

24-ethyl-3,10,28-trihydroxy-14-methoxy-25-methyl-5,26-dioxo-12,18,20-trioxa-25-azaheptacyclo[15.11.1.0²,¹⁵.0⁴,¹³.0⁶,¹¹.0²¹,²⁹.0²²,²⁷]nonacosa-1(29),2(15),3,6(11),13,21,23,27-octaen-7-yl acetate

C31H29NO11 (591.1741)


   

1-{1-carboxy-3-[(3-carboxy-3-{2-[2-(2-carboxy-2-hydroxy-5-oxopyrrolidin-1-yl)ethoxy]-2-oxoethyl}-1,3-dihydroxypropylidene)amino]propyl}-2-hydroxy-5-oxopyrrolidine-2-carboxylic acid

1-{1-carboxy-3-[(3-carboxy-3-{2-[2-(2-carboxy-2-hydroxy-5-oxopyrrolidin-1-yl)ethoxy]-2-oxoethyl}-1,3-dihydroxypropylidene)amino]propyl}-2-hydroxy-5-oxopyrrolidine-2-carboxylic acid

C22H29N3O16 (591.1548)


   

24-ethyl-3,7,28-trihydroxy-14-methoxy-25-methyl-5,26-dioxo-12,18,20-trioxa-25-azaheptacyclo[15.11.1.0²,¹⁵.0⁴,¹³.0⁶,¹¹.0²¹,²⁹.0²²,²⁷]nonacosa-1(29),2(15),3,6(11),13,21,23,27-octaen-10-yl acetate

24-ethyl-3,7,28-trihydroxy-14-methoxy-25-methyl-5,26-dioxo-12,18,20-trioxa-25-azaheptacyclo[15.11.1.0²,¹⁵.0⁴,¹³.0⁶,¹¹.0²¹,²⁹.0²²,²⁷]nonacosa-1(29),2(15),3,6(11),13,21,23,27-octaen-10-yl acetate

C31H29NO11 (591.1741)


   

(17s)-24-ethyl-3,10,28-trihydroxy-14-methoxy-25-methyl-5,26-dioxo-12,18,20-trioxa-25-azaheptacyclo[15.11.1.0²,¹⁵.0⁴,¹³.0⁶,¹¹.0²¹,²⁹.0²²,²⁷]nonacosa-1(29),2(15),3,6(11),13,21,23,27-octaen-7-yl acetate

(17s)-24-ethyl-3,10,28-trihydroxy-14-methoxy-25-methyl-5,26-dioxo-12,18,20-trioxa-25-azaheptacyclo[15.11.1.0²,¹⁵.0⁴,¹³.0⁶,¹¹.0²¹,²⁹.0²²,²⁷]nonacosa-1(29),2(15),3,6(11),13,21,23,27-octaen-7-yl acetate

C31H29NO11 (591.1741)


   

(17s)-24-ethyl-3,7,28-trihydroxy-14-methoxy-25-methyl-5,26-dioxo-12,18,20-trioxa-25-azaheptacyclo[15.11.1.0²,¹⁵.0⁴,¹³.0⁶,¹¹.0²¹,²⁹.0²²,²⁷]nonacosa-1(29),2(15),3,6(11),13,21,23,27-octaen-10-yl acetate

(17s)-24-ethyl-3,7,28-trihydroxy-14-methoxy-25-methyl-5,26-dioxo-12,18,20-trioxa-25-azaheptacyclo[15.11.1.0²,¹⁵.0⁴,¹³.0⁶,¹¹.0²¹,²⁹.0²²,²⁷]nonacosa-1(29),2(15),3,6(11),13,21,23,27-octaen-10-yl acetate

C31H29NO11 (591.1741)